Clinical trials: Locally Advanced Rectal Cancer
Rectal Neoplasms
Study for Wait and Watch Suitable in Rectal Cancer
One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery.
- Trial name
- ARROW (NCT06252142)
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Centre
Rectal Cancer
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
The investigators planned a phase I study of preoperative CRT with capecitabine plus temozolomide inpatients with locally advanced resectable rectal cancer: 1) the role of temozolomide as a radiosensitizer has been well…
- Trial name
- NCT01781403
- Testing
- Temozolomide
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Locally Advanced Resectable Rectal Cancer
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Trial name
- NCT07454720
- Testing
- Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 165 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Rectal Cancer
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
The study aims to evaluate the efficacy and safety of fruquintinib combined with mFOLFOX6 + synchronous radiotherapy as neoadjuvant therapy in middle and low locally advanced rectal cancer patients with no previous anti-tumor…
- Trial name
- NCT05575635
- Testing
- fruquintinib + concurrent radiotherapy + chemotherapy
- Volunteers
- 40 people
- Sponsor
- Henan Provincial People's Hospital
Rectal Cancer
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinoma
- Trial name
- NCT01434147
- Testing
- preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
- Where
- 7 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Cancer
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Microsatellite stable (MSS) locally advanced rectal cancer (LARC) remains a major therapeutic challenge despite advances in multimodal treatment.
- Trial name
- NCT07594925
- Testing
- Sintilimab, Chemotherapy Drugs, radiotherapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the…
- Trial name
- NCT03516708
- Testing
- Epacadostat, Short-course radiation therapy, CAPOX chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Patients diagnosed with locally advanced very low rectal cancer were chosen to participate in a comprehensive neoadjuvant therapy (TNT) protocol.
- Trial name
- TRACE-LE (NCT05969847)
- Testing
- split-course hypofraction radiotherapy, CAPOX, Envafolimab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- 池畔
Rectal Cancer
Rosuvastatin in the Treatment of Rectal Cancer
This study will evaluate whether the addition of Rosuvastatin to standard chemoradiation therapy for the treatment of locally advanced rectal cancer may improve the pathological response rate and survival compared to standard…
- Trial name
- NCT02569645
- Testing
- Rosuvastatin
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- AHS Cancer Control Alberta
Rectal Cancer
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer.
- Trial name
- RCNAC (NCT05201430)
- Testing
- FOLFOXIRI, CapeOX
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Locally Advanced Unresectable or Stage IV Colorectal Cancer
Stage IV Colorectal CA ALIMTA
Phase I: The primary objective of the Phase 1 portion of this study is to determine the Maximum tolerated dose and the recommended Phase 2 dose of ALIMTA plus oxaliplatin when given with folate and vitamin B-12 supplementation in…
- Trial name
- NCT00166465
- Testing
- ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Rectal Cancer
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens is planned for 15 locally advanced…
- Trial name
- NCT01395667
- Testing
- CCRT
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Cancer
Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer.
Clinical objective of the study is to compare the rates of pathologic response, acute toxicity and sphincter preservation with two schedules of preoperative regiment in patients with locally advanced rectal cancer.
- Trial name
- NCT01814969
- Testing
- Hyperfractionated Radiochemotherapy, Hyperfractionated Radiotherapy
- Where
- Poland
- Volunteers
- 260 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Rectal Cancer, Radiotherapy
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small…
- Conditions
- Rectal Cancer, Radiotherapy, Toxicity Due to Radiotherapy
- Trial name
- NCT06160570
- Testing
- Intensive Modulated Radiation Therapy, 3-Dimension Conformal Radiation Therapy
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Rectal Neoplasms
Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Standard care for locally advanced rectal cancer consists in a neoadjuvant therapy followed by surgery. Morbidity and mortality remain high after rectal surgery, and often linked with quality of life impairment.
- Trial name
- NCT05534841
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Rectal Cancer
Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen
This study is designed to test the efficacy and safety of Total Neoadjuvant Treatment plus SHR1210（an anti-PD-1 Inhibitor) for High-risk locally advanced Rectal Cancer, Meanwhile, screening effective Biomarker base on neoantigen.
- Trial name
- NCT04340401
- Testing
- SHR-1210, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
- Trial name
- NCT07446465
- Testing
- Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ye Xu